Last reviewed · How we verify

Diprivan — Competitive Intelligence Brief

Diprivan (Diprivan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed Cytochrome P450 2C9, Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 4 Other Small molecule Live · refreshed every 30 min

Target snapshot

Diprivan (Diprivan) — St. Antonius Hospital.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diprivan TARGET Diprivan St. Antonius Hospital marketed Cytochrome P450 2C9, Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diprivan — Competitive Intelligence Brief. https://druglandscape.com/ci/diprivan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: